LOS ANGELES, CALIFORNIA — August 27, 2025 — Leads & Copy — Renovaro Inc. (NASDAQ:RENB) announced it will change its corporate name to Lunai Bioworks, Inc. to reflect its strategic direction and expertise in AI-powered biodefense, drug discovery, and diagnostics.
The company aims to enhance collaboration across research, development, and commercialization teams after its merger with BioSymetrics. Lunai Bioworks inherits collaborations with biopharmaceutical companies, including Janssen, Pfizer, Merck, Supernus Pharma, and Deerfield Cures, validating its platforms in translational analytics, in vivo modeling, and machine vision.
Lunai’s CEO, David Weinstein, said the new name captures the company’s focus on AI-driven biodefense and drug discovery. The name change was approved by the Board of Directors, and its stock will continue to trade on Nasdaq under the ticker symbol RENB until further notice.
Contact:
David Weinstein
Chief Executive Officer
investors@renovaro.com
Source: Renovaro Biosciences
